Replies to post #342226 on Elite Pharmaceuticals Inc (ELTP)

[YJ4LIFE]

Everyone should read this and stop hating our great CEO, Nasrat Hakim. He is looking out for us!

[WeeZuhl]

This is why Nasrat was smart to switch strategies. We’re lucky to have him at the helm. Pressure is building, won’t stay at these levels much longer. Significant revenue increases can’t be ignored by the street.

https://www.reuters.com/article/us-purdue-pharma-investigations-opioids/u-s-states-seek-2-2-trillion-from-oxycontin-maker-purdue-pharma-filings-idUSKCN25D2EG

1. Comparing Elite with Purdue is delusional for any number of reasons. Nobody really believes there is any rational comparison between the business practices of these two companies. Purdue's behavior is not a legal risk for Elite. Elite manufactured and sold generic opioids since 2010 without any legal interference ever.

2. There is zero evidence of any "pressure" building in the stock price, which is a direct result of over 1 billion shares outstanding.

3. "Significant revenue increases" will require additional ANDA approvals. The Concerta application is not imminent and FDA approval before CY2022 is extremely unlikely.